Product Information
RIFAMPIN 300 MG CAPSULE is a generic product labeled by Major Pharmaceuticals, priced at $0.6789 per EA under NDC 00904731561. Its NADAC has been published 67 times since Jun 25, 2025.
FDA first approved this application on Aug 21, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904731561
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIFAMPINApproval Type
Generic (ANDA)
FDA Application
ANDA090034FDA Approved
8/21/2013
TE Code
AB
On Market Since
2/25/2025
Pharmacological Classes
Price Statistics
The NADAC for RIFAMPIN 300 MG CAPSULE has been published 67 times since Jun 25, 2025, and over the history we have for it it has declined 6.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6789 per EA |
|---|---|
| All-time high | $0.7246 (Jul 16, 2025) |
| All-time low | $0.6789 (Sep 23, 2026) |
| 52-week high | $0.7186 |
| 52-week low | $0.6789 |
| Median price | $0.6921 |
| Average price | $0.6968 |
| Largest weekly change | -2.3% (Nov 19, 2025) |
| Weeks tracked | 67 |
| Tracking since | Jun 25, 2025 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rifampin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Rifamycin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIFAMPIN 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIFAMPIN 300 MG CAPSULE, manufactured by Major Pharmaceuticals, is $0.6789 per EA (NDC 00904731561), effective Sep 30, 2026.
How has the price of RIFAMPIN 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIFAMPIN 300 MG CAPSULE has declined 6.3%. It has been tracked across 67 weekly CMS publications since Jun 25, 2025.
What are the highest and lowest recorded NADAC prices for RIFAMPIN 300 MG CAPSULE?
Since Jun 25, 2025, the NADAC for RIFAMPIN 300 MG CAPSULE has ranged from a low of $0.6789 (Sep 23, 2026) to a high of $0.7246 (Jul 16, 2025), with a median of $0.6921 per EA.
Are there cheaper alternatives to RIFAMPIN 300 MG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIFAMPIN 300 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures RIFAMPIN 300 MG CAPSULE?
RIFAMPIN 300 MG CAPSULE (NDC 00904731561) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.